Library / regulatory-reference
Netherlands: Medicines Evaluation Board (MEB)
Audience: administrators-policy, researchers-scientists ยท Review state: published
The national authority
The Medicines Evaluation Board, known by its Dutch initials CBG-MEB, is the Netherlands' national regulatory authority for medicines.
The Netherlands is a significant pharmaceutical economy, and the board works within the European regulatory network as one of its most active assessment contributors.
How products enter the market
Medicines require marketing authorization through national or European procedures after evaluation of quality, safety and efficacy, with inspection and licensing handled alongside partner agencies.
Post-market work includes safety monitoring within the European alert network, with the board also running veterinary-medicines regulation and contributing to European shortage management.
Regional and international role
The board is among the most frequent lead assessors in the European regulatory network, and its scientific opinions shape authorizations across the continent.
Its hosting of major European regulatory functions underscores its central position in European medicines oversight.
Using this profile
The board publishes regulations, assessment information and alerts in Dutch and English through its official portal, which is the primary source for current rules and listed in this profile's internal reference record.
For cross-country comparison: the Netherlands illustrates the assessor-powerhouse member state: a national agency whose scientific work drives European decisions.
Limitations
Educational profile of a national regulatory system, current as of drafting. It simplifies routes and classes and is not legal, regulatory, or clinical advice. Filing and compliance decisions must be confirmed against the authority's current published rules and, where needed, professional regulatory counsel.